Navigation Links
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
Date:9/10/2009

rders due to a nonsense mutation. Restoring functional CFTR protein may enable ataluren to address the underlying cause of nmCF and change the course of the disease. Currently available therapies for CF focus only on the alleviation of symptoms.

"We are excited to expand the ataluren registration program to include nmCF, an area of significant unmet medical need," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics. "We are hopeful that this Phase 3 trial together with our ongoing studies in nmDMD/BMD, will add to a growing body of data demonstrating ataluren's potential for treatment of patients with nonsense mutation genetic disorders."

About Cystic Fibrosis (CF)

CF is a life-threatening genetic disease that causes serious lung infections and digestive complications. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. Genetic testing is required to confirm a complete diagnosis and to determine if a patient's disease is caused by a nonsense mutation. It is estimated that nonsense mutations are the cause of CF in 10 percent of patients in the United States and Europe and over 50 percent of patients in Israel. Available treatments for CF are designed to alleviate symptoms rather than correct the underlying cause of the disease. These treatments include chest physical therapy to clear thick mucus from the lungs, antibiotics to treat lung infections, and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. More information regarding CF is available through the Cystic Fibrosis Foundation (www.cff.org).

About Atal
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 03, 2015 Photo-Eyewear™ ( http://www.PhotoEyewear.com ... to PogoTec™, Inc. ( http://www.PogoTec.com ) to better ... device products and technologies it is developing and plans ... business divisions, PogoTec™ will provide focused resources to drive ... , , On-Track™ – There are ...
(Date:6/3/2015)... GEA's Panther™ NS3006L is a ... fully-equipped laboratory unit that is designed for continuous operation ... plants. The Panther™ NS3006L achieves the same results as ... easy installation with simple operation, quick maintenance and is ... used in many different industries, such as food, dairy, ...
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ ... a clinical-stage company developing new therapeutics that target the ... Food and Drug Administration (FDA) has granted the company ... acute myeloid leukemia (AML). APTO-253, a first-in-class inducer of ... in a Phase Ib clinical trial in patients with ...
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3
... tiny scaffolds to be used as delivery vehicles to drop ... as Alzheimer,s and Parkinson,s. Owing to the versatility and ... facilitating the growth of cells and could be designed specifically ... In their study published today, Tuesday 20 September, ...
... The Southeastern Universities Research Association today announced that Neal ... and former chief White House science advisor, would receive ... Board meeting on November 9. The award honors ... of strengthening the scientific and technical capabilities of the ...
... WORCESTER, Mass. and TORONTO, Sept. 19, 2011 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), ... for the treatment of breast, prostate, and other ... of Expert Opinion on Biological Therapy , ...
Cached Biology Technology:Lasers light the path to neuron regeneration 2SURA to honor former NSF director, White House science advisor 2SURA to honor former NSF director, White House science advisor 3Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 2Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 3Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 4Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 5
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... It just got easier to pinpoint biological hot spots in ... a pinpoint. Microscopic algae are called phytoplankton and range from ... being 1/100th the size of a human hair. But as ... of Vancouver Island, British Columbia, are big players when it ...
... MD FASEB MARC (Minority Access to Research Careers) ... American Society for Bone & Mineral Research (ASBMR) 2010 ... 2010. These awards are meant to promote the ... the mainstream of the basic science community and to ...
... October 6, 2010 - A first-of-its-kind study that tracked the ... tagged in the Hudson River discovered that these fish move ... south as Georgia and as far north as Nova Scotia, ... will need to address long-range oceanic threats to the species ...
Cached Biology News:UW-built device reveals invisible world teeming with microscopic algae 2Study provides data that can inform Atlantic sturgeon recovery efforts 2Study provides data that can inform Atlantic sturgeon recovery efforts 3
IHC detection kit for BrdU in cells and tissues...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Tissue culture grade....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Biology Products: